OUTCOMESML
LIVE

Serial Number

98774561

Owner

EntityRisk, Inc.

Attorney

Tracy Wells

First Use Date

May 5, 2024

Filing Date

Sep 27, 2024

Add to watchlist:

No watchlists yet
View on USPTO

OUTCOMESML Trademark

Serial Number: 98774561

OUTCOMESML is a trademark filed by EntityRisk, Inc. on September 27, 2024. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

EntityRisk, Inc. (8 trademarks)

300 Carnegie Center Suite 150
Princeton, NJ 08540

Entity Type: 03

Trademark Details

Filing Date

September 27, 2024

Registration Date

Not Registered

First Use Anywhere

May 5, 2024

First Use in Commerce

May 5, 2024

Goods & Services

Design, development, and implementation of software for predicting asset values, determine pricing, evidence-generation, contracting by utilizing a pricing and generalized value module and commercial due diligence module, building recommendations based on clinical evidence of benefit and risk, expediting value assessment and providing qualitative, evidence based approach to support decisions about pricing, evidence generation and contracting. Providing an interactive website featuring technology that allows users to enter, access, and synthesize information and generate reports for use in consulting with executives and businesses, Software as a service (SAAS) featuring software for predicting business asset values, determining pricing, evidence generation, and contracting by utilizing a pricing and generalized value module and commercial due diligence module.

Computer software platforms, downloadable, for predicting asset values, determine pricing, evidence-generation, contracting by utilizing a pricing and generalized value module and commercial due diligence module, building recommendations based on clinical evidence of benefit and risk, expediting value assessment and providing qualitative, evidence based approach to support decisions about pricing, evidence generation and contracting, forecasting the empirical distribution of real-world clinical effectiveness for pipeline candidates or newly launched medicines to support commercial decision making and/or customer engagement.

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jan 2, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jan 2, 2026 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 8, 2025 GNFN
FINAL REFUSAL E-MAILED
Oct 8, 2025 GNFR
FINAL REFUSAL WRITTEN
Oct 8, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 8, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 7, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 7, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 7, 2025 GNRN
NON-FINAL ACTION E-MAILED
Apr 7, 2025 GNRT
NON-FINAL ACTION WRITTEN
Apr 7, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 3, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 2, 2025 NWOS
NEW APPLICATION ENTERED
Sep 27, 2024 NWAP